New Microbiological Techniques for the Diagnosis of Bacterial Infections and Sepsis in ICU Including Point of Care

Anna Maria Peri 1 · Adam Stewart 1,2 · Anna Hume 2,3 · Adam Irwin 1,4 · Patrick N A Harris 1,3

Accepted: 31 May 2021 / Published online: 16 June 2021 © Crown 2021

Abstract
Purpose of Review The aim of this article is to review current and emerging microbiological techniques that support the rapid diagnosis of bacterial infections in critically ill patients, including their performance, strengths and pitfalls, as well as available data evaluating their clinical impact.

Recent Findings Bacterial infections and sepsis are responsible for significant morbidity and mortality in patients admitted to the intensive care unit and their management is further complicated by the increase in the global burden of antimicrobial resistance. In this setting, new diagnostic methods able to overcome the limits of traditional microbiology in terms of turn-around time and accuracy are highly warranted. We discuss the following broad themes: optimisation of existing culture-based methodologies, rapid antigen detection, nucleic acid detection (including multiplex PCR assays and microarrays), sepsis biomarkers, novel methods of pathogen detection (e.g. T2 magnetic resonance) and susceptibility testing (e.g. morphokinetic cellular analysis) and the application of direct metagenomics on clinical samples. The assessment of the host response through new “omics” technologies might also aid in early diagnosis of infections, as well as define non-infectious inflammatory states.

Summary Despite being a promising field, there is still scarce evidence about the real-life impact of these assays on patient management. A common finding of available studies is that the performance of rapid diagnostic strategies highly depends on whether they are integrated within active antimicrobial stewardship programs. Assessing the impact of these emerging diagnostic methods through patient-centred clinical outcomes is a complex challenge for which large and well-designed studies are awaited.

Keywords Rapid diagnostics · Bloodstream infection · Sepsis · Antimicrobial resistance · Critical care

Introduction
Bacterial infections are common in adults and children admitted to the intensive care unit (ICU). In a cohort of 198 ICUs in 24 European countries, including 3147 patients, 37.4% had sepsis, with 24.7% presenting with sepsis on admission [1]. Infections in these patients are associated with significant morbidity, mortality and cost [2]. The risks associated with infection also result in high usage of antibiotics; in a global point-prevalence study, 70% of all ICU patients were receiving at least one antibiotic on any given day [3]. Being able to rapidly and accurately, determine the causative pathogen in bacterial infections is a critical step in clinical management. Furthermore, with the growing global burden of antimicrobial resistance, rapid antimicrobial susceptibility testing (AST) is increasingly important to guide therapy. Given the necessity of reducing excessive antibiotic use, we also urgently need diagnostic strategies that can help exclude the presence of infection and define non-infectious inflammatory states for which antibiotics are not required [4].

Current diagnostic methods in patients presenting with sepsis largely rely on the culture of micro-organisms from blood to detect bacteraemia. However, not only is this approach relatively slow and laborious, culture-based systems suffer from a number of pre-analytical limitations that may affect performance, such as inadequate blood volume collection,
prior antibiotic exposure and delays in laboratory processing or transportation, especially if laboratory facilities are off-site. Furthermore, even when an organism is cultured, definitive identification and susceptibility testing may be delayed for few days. Contamination is a frequent problem that may occur at blood culture (BC) collection and may drive inappropriate antibiotic use, misdirect clinical diagnosis and expose patients to unnecessary toxicities [5]. There are also many fastidious pathogens, which can be challenging to culture in standard automated systems [6].

While, in some respects, clinical microbiology laboratories have relied upon techniques that have evolved little for many decades, there are a number of emerging or newly established technologies that are set to revolutionise how microbial diagnostics may be performed in the near future. Mass-spectrometry methods were not part of routine laboratory practice a decade ago, yet matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF) has now rapidly replaced conventional bacterial identification methods in many laboratories, with step-wise improvements in turn-around times (TATs), accuracy and reduced costs [7]. This article aims to review the current state of the art, as well as new and emerging technologies, that may improve our capacity for rapid and accurate microbiological diagnosis in patients with significant bacterial infections and sepsis.

**Established Rapid Diagnostic Methods**

In recent years, implementation of existing rapid diagnostic technologies and improved automated workflow systems into clinical laboratories has enabled better delivery of healthcare [8, 9]. Currently, automated BC systems are the gold standard for bloodstream infection detection [10]. Many automated BC systems exist (e.g., BACTEC™ FX, BacT/ALERT®) which apply different methods to detect organism growth (i.e. different nutrients and antimicrobial binding agents) and their performance has been compared [11–15]. In one study, a shorter time to detection and bacterial recovery rate was observed in the BacT/ALERT® VIRTUO system when compared to others [11]. Bottles containing antibiotic binding agents typically have better bacterial recovery rates [16, 17]. Most automated BC systems have an internal sensor that detects carbon dioxide or pH as an indicator of microbial growth [18]. Microscopy and Gram stain on sterile fluids such as blood is a crucial step in providing critical information to inform diagnosis and management of severe infection. Despite automated Gram staining systems, interpretation remains laborious and time intensive, and is still operator dependent [19]. Automated image acquisition and machine learning–based approaches for automated Gram stain classifications have been explored, showing promising accuracy although still far from being able to perform as fully automated systems [20]. Early identification of important organisms such as *Staphylococcus aureus* directly from BC by coagulate testing has improved TAT and is inexpensive and easily incorporated into standard workflows [21, 22]. Rapid antimicrobial susceptibility methods have been developed to reduce the time to results. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has developed a standardised rapid method based on disc diffusion that offers antimicrobial susceptibility results within 4–8 h from BC positivity [23–25]. Detection of common mediators of resistance, such as β-lactamases, direct from clinical samples, is also possible. Rapid detection of clinically relevant carbapenemase- and extended-spectrum β-lactamase (ESBL)–producing organisms can be achieved through a variety of commercial assays (e.g., RAPIDEC® CARBA NP, ESBL-NP) [26, 27]. Using a pH indicator to detect carbapenem hydrolysis, accurate and rapid (under 2 h) detection of carbapenemases from clinical isolates using a short incubation culture time can be demonstrated [28]. Similar reductions in TAT have been seen with rapid ESBL detection assays when compared with conventional susceptibility testing [29].

Direct antigen testing of clinical samples has aided in the rapid species identification. Urine antigen testing has been widely used for pathogen detection in respiratory infections caused by *Legionella pneumophila* and *Streptococcus pneumoniae* [30]. Antigens shed from these organisms and excreted in the urinary tract are usually detected by enzyme immunoassay (EIA) or lateral flow assay (LFA) [31]. Despite a shortened TAT, antigen testing suffers from poor sensitivity and specificity (for example, in children colonised with *S. pneumoniae*) and is unable to provide antibiotic susceptibility profiles or other epidemiological data [32]. Rapid antigen detection from other clinical samples such as blood, throat swab, synovial fluid, pleural fluid and cerebrospinal fluid (CSF) has been examined previously but is not as commonly used in practice [33–35]. A large retrospective multicentre study assessed the clinical utility of rapid bacterial antigen detection using latex agglutination and concluded that they were costly and of no detectable clinical benefit [36]. Nucleic acid amplification testing (NAAT) or polymerase chain reaction (PCR) tests are a reliable non-culture microbial detection method, frequently used in laboratories around the globe for the diagnosis of a wide array of microbial pathogens. In addition, multiplex PCR incorporates several primers and probes within one reaction tube to amplify gene targets from multiple pathogens [37]. This highly sensitive approach increases the diagnostic yield and can be used on many clinical specimens including respiratory secretions, CSF, sterile fluids and diarrhoeal faeces. Limitations of PCR testing include reporting of incidental results, a lack of distinction between colonisation versus infection, requirement for experienced operators and a dedicated laboratory environment, and the absence of antibiotic susceptibility data [38]. Furthermore, PCR
will only detect pathogens specifically targeted by the assay design. Rare and unexpected organisms, or strains with variants in target sequences, may be missed. The accuracy and favourable positive predictive value rests upon the correct clinical setting, e.g. *Clostridoides difficile* PCR testing in diarrhoea and multiplex bacterial PCR testing on CSF with pleocytosis.

The immune response to severe infection and sepsis is complex with a wide variety of inflammatory and anti-inflammatory mediators released [39]. Numerous biomarkers have been explored to assist in the rapid diagnosis of serious infections in ICU. Along with the leucocyte count, the most established of these is C-reactive protein (CRP). CRP is an acute phase protein that increases following interleukin-6 secretion by macrophages and T-cells, and has been shown to be a sensitive but not specific marker of sepsis [40]. Procalcitonin is a peptide secreted by many cells in the body in response to a pro-inflammatory stimulus, and may be more specific as a marker of bacterial infection than CRP [41]. The complexity of the host response is reflected in the range of biomarkers under investigation as potential markers of serious infection, including acute phase reactants, cytokines (in particular interleukin-6 and interleukin-8), soluble receptors and cell surface and endothelial markers [42]. Used individually or in combination, the role of biomarkers is to stratify the risk of serious infection, or crudely predict the likely aetiology and guide decisions on initiating or stopping antibiotics. Despite the limited nature of their predictions, evidence from randomised trials appears to support a role in ICU. While of limited value in guiding treatment initiation, the use of procalcitonin supported decisions to stop antibiotics, and reduced the duration of antimicrobial therapy in both adult and neonatal ICU [43, 44].

**New and Emerging Methods**

In recent years, new rapid diagnostic tests (RDTs) have emerged that are able to provide pathogen identification and resistance profile within a short TAT. Their potential in improving patient management is promising although studies on their clinical impact remain scarce [45].

**Emerging Diagnostics for Meningitis and Severe Respiratory Infections**

Multiplex PCR are increasingly used in clinical practice for the diagnosis of central nervous system infections and pneumonia in the ICU setting. The BioFire FilmArray Meningitis/Encephalitis panel (bioMérieux) is an FDA-cleared, multiplex PCR detecting 14 pathogens from CSF in 1 h. Estimated sensitivity and specificity are 90 and 97% respectively [46] although evidence is scarce about its impact on patients’ outcomes [47, 48].

Similarly, the BioFire FilmArray Pneumonia plus Panel can detect 27 microorganisms and 7 resistance markers on respiratory specimens, including nosocomial pathogens associated to hospital-acquired or ventilator-acquired pneumonia, and its role in improving antimicrobial stewardship (AMS) in critically ill patients with coronavirus disease 2019 has been suggested [49]. Other multiplex PCR (e.g. Seegene Allplex Respiratory panel) have narrower panels, more useful for community-acquired respiratory infections [50].

**Nucleic Acid Detection from Blood Cultures**

Several techniques are emerging for pathogen identification from positive BCs. The BioFire FilmArray BC identification panel (BCID, bioMérieux) is a multiplex PCR which detects 24 pathogens and 3 resistance genes from positive cultures with good analytical performance [51, 52]. In a study on ICU patients with culture-confirmed sepsis, this test reduced the time to optimal treatment compared to standard BC [53] and a role in diagnosing ventilator-associated pneumonia has also been suggested [54]. A new version of this test has been recently released (BioFire BCID2) with a broader panel including 43 targets, although clinical evaluation studies are awaited.

In the specific setting of *S. aureus* bacteraemia, the Xpert MRSA/SA BC Assay (Cepheid) can detect through a real-time PCR methicillin-susceptible and methicillin-resistant *S. aureus* (MRSA) from positive BC. This test is associated with high sensitivity and specificity [55] and its automation easily fits the laboratory routine. Similarly, the Cepheid Xpert Carba-R assay is designed for the detection of genes encoding for carbapenemases from cultured bacterial isolates; however, it has been assessed as a method of direct detection from BC in settings with high carbapenem resistance prevalence [56]. The Verigene system (Luminex) uses multiplex PCRs and subsequent microarray hybridisation for detection of 22 bacteria and their resistance determinants from positive BC [57, 58], and comprises two different panels, for Gram positives and Gram negatives, whose choice can be driven by the Gram stain results. Verigene has proved able to identify susceptibility to new β-lactam/β-lactamase inhibitors [59], and when implemented within an AMS program, reduced the time to optimal therapy in bacteraemic patients [60, 61].

Other technologies applied to positive BC include fluorescent in situ hybridisation (FISH) using peptide nucleic acid (PNA) probes targeting 16S or 18S rRNA of bacteria and fungi respectively. PNA-FISH (AdvanDx) comprises 4 different panels and improvement of early treatment appropriateness has been demonstrated when integrated with AMS [62, 63].
Pathogen Detection Direct from Blood

To skip the time-consuming step of BC growth, new technologies are emerging that may be used directly on whole blood. Among NAAT-based methods, Lightcycler SeptiFast Test (Roche) and Magicplex Sepsis Real-Time test (Seegene) are real-time PCR assays detecting several microorganisms and some markers of resistance from whole blood. Despite having broad panels, their low sensitivity [64–68] makes recommendations about their clinical use difficult. Indeed, SeptiFast was recently discontinued.

The combination of pathogen-specific PCR with miniaturised magnetic resonance has been realised in the T2 magnetic resonance (T2MR), able to identify microorganisms from whole blood with a brand-new methodology; specifically, the DNA amplified by PCR binds by complimentary probes to paramagnetic nanoparticles, whose signal is identified by T2MR [69]. The T2Candida test (T2 Biosystems) is an automated system which identifies the most common Candida species with high negative predictive values across a wide range of pre-test probabilities [70, 71]. T2Candida has shown to shorten the time to effective antifungal therapy and reduce inappropriate empirical treatments, as well as to predict poor clinical outcomes in suspected and proven candidemia [71]. Similarly, the T2Bacteria detects the ESKAPE bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli) [72–74]. However, due to the limited panel of pathogens and resistance genes detected, its clinical benefit remains uncertain [75]. MALDI-TOF has been used directly on clinical samples including blood, urine [76] and CSF [77]. PCR/ESI-MS combines pathogen-specific PCR with mass spectrometry based on electrospray ionisation (ESI-MS): the IRIDICA system (Abbott) could detect 780 microorganisms and 4 resistance genes from various samples. However, despite promising performances, this assay has been discontinued [78] illustrating that a clear benefit of implementing these expensive tests is not yet apparent.

Direct Metagenomics

Metagenomics-based assays are among the most promising emerging tools in clinical microbiology as they can potentially identify any microorganisms in a given sample.

16S metagenomics is based on amplification through universal primers of the bacterial 16S rRNA gene, followed by amplicon sequencing, which leads to bacterial identification and taxonomic profiling [79]. SepsiTest (Molzym) is a semiautomated assay based on such technology used for pathogen detection from blood: despite being able to detect polymicrobial infections and fastidious organisms, its role in informing clinical decisions is limited as it suffers of low sensitivity and does not provide AST [64]. Compared to 16S metagenomics, shotgun metagenomics is based on untargeted next-generation sequencing (NGS), which reads complete bacterial genomes by massive parallel sequencing, providing a precise taxonomic resolution of all pathogens in a sample and potentially detects markers of antimicrobial resistance [80]. iDTECT Dx Blood (PathoQuest) is based on untargeted NGS and has been demonstrated to detect more clinically relevant microorganisms than conventional microbiology in immunocompromised patients, with a high negative predictive value [81]. Similarly, Karius NGS Plasma Test (Karius), which can identify microbial cell-free DNA from over 1200 microorganisms, showed 93.7% sensitivity compared to BCs in patients with suspected sepsis [82] and may be able to identify clinically relevant pathogens in blood in the days before the onset of bloodstream infections [83].

The ability of shotgun-metagenomics to perform a comprehensive analysis of the microbial genetic material in a biological sample holds great promise. However, limitations exist that make the implementation of these assays complex and a limited real-life clinical impact for diagnosis of infection has been reported by some studies [84, 85]. The frequent detection of contaminants and colonisers affects NGS specificity and complicates the interpretation of results in diagnosing bloodstream infections; to address this limitation, a recent study on patients with septic shock showed the utility of the sepsis indicating quantifier (SIQ) score as a means of discriminating clinically relevant pathogens from the others [86]. Moreover, NGS sensitivity is decreased in samples with high nucleic acid background such as blood, thus requiring human DNA depletion. Such techniques also lack standardisation of analysis methods. Frequently, bioinformatics skills needed to analyse NGS data are unavailable in a standard diagnostic laboratory and may require external expertise or data transfer to other facilities. This introduces delays, as well as additional costs, challenges in computational and data storage capacity, data privacy issues and complexities for accreditation with regulatory authorities.

New Rapid AST Methods

The detection of resistance genes is not always reliable to reflect the actual susceptibility pattern of the identified pathogen. The FDA-approved Accelerate Pheno system (Accelerate Diagnostics) can detect 16 microorganisms from positive BC based on FISH technology as well as perform phenotypic AST by morphokinetic cellular analysis [87–89], with over 96% categorical agreement in comparison to standard methods [89, 90] (Table 1). Studies showed this test improves achievement of and time to optimal therapy in patients with bacteraemia [92, 93].

Advances in microfluidics, electronics, optic and biosensor techniques are promising approaches for next-generation rapid AST and at the early stages of translation into practice. Evidences on their role to address point of care testing
Table 1 Commercially available rapid diagnostic tests for the diagnosis of bloodstream infections

| Technology                        | Assay (manufacturer)                          | TAT (h) | Organisms detected                                                                 | Resistance genes detected                                                                 | Sensitivity/ specificity (%) | Ref |
|-----------------------------------|-----------------------------------------------|---------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------------------------|-----|
| From positive blood cultures     |                                               |         |                                                                                    |                                                                                            |                              |     |
| Multiplex PCR                     | The BioFire FilmArray blood culture identification panel 2 (BCID2) (bioMérieux) | 1       | 11 Gram positives Staphylococcus spp., Staphylococcus aureus, S. epidermidis, S. lugdunensis, Streptococcus spp., S. agalactiae, S. pyogenes, S. pneumoniae, E. faecalis, E. faecium, L. monocytogenes | mecA/C, mecA/C and MREJ (MRSA), van A/B, blakPC, blalMP, blaoXA-48, blaNDM, blavIM, mcr-1, CTX-M | 91–96/98–100 | [51–53] |
|                                  |                                               |         | 15 Gram negatives A. calcoaceticus-baumannii complex, B. fragilis, H. influenzae, N. meningitidis, P. aeruginosa, S. maltophilia, Enterobacteriales, E. coli, E. cloacae complex, K. aerogenes, K. oxytoca, K. pneumoniae group, Proteus spp., Salmonella, S. marcescens | |                              |                              | |
| Real-time multiplex PCR DNA microarray | Xpert MRSA/SA Blood Culture Assay (Cepheid) | 1–2     | 13 Gram positives Staphylococcus spp., Staphylococcus aureus, S. epidermidis, S. lugdunensis, Streptococcus spp., S. agalactiae, S. pneumoniae, S. pyogenes, S. anginosus, E. faecalis, E. faecium, Micrococcus spp., Listeria spp. | mecA, van A/B | 93–100/94.5–100 | [58] |
|                                  | Verigene Gram Positive Blood Culture Test (Luminex) | 2.5     | 9 Gram negatives E. coli, K. pneumoniae, K. oxytoca, S. marcescens, Citrobacter spp., Enterobacter spp., Proteus spp., Acinetobacter spp., P. aeruginosa | mecA, blacTXM, blakPC, blaoXA-48, blalMP, blavIM, blaNDM | 98/100 | [57] |
| In situ hybridization PNA FISH (AdvanDx) | -Staphylococcus aureus/CNS | 1.5–3   | S. aureus, CoNS | - | 88–98/98 | [91] |
|                                  | -E. faecalis/EO PNA FISH (AdvanDx)             |         | E. faecalis, E. faecium, Enterococcus spp. | - | 97/100 | [91] |
|                                  | -Gram-Negative PNA FISH (AdvanDx)              |         | E. coli, K. pneumoniae, P. aeruginosa | - | 99/98 | [91] |
| In situ hybridization + morphokinetic cellular analysis for AST Quick-FISH | Accelerate PhenoTest BC (Accelerate Diagnostics) | 0.5     | 6 Gram positives CoNS spp., E. faecalis, E. faecium, S. aureus, S. lugdunensis, Streptococcus spp. | AST results as MIC (same 4 panels of PNA-FISH) | 98–100/98–100 | [91] |
|                                  |                                               | 1 (7 for A-S-T) | 8 Gram negatives A. baumannii, Citrobacter spp., Enterobacter spp., E. coli, Klebsiella spp., Proteus spp., P. aeruginosa, S. marcescens | 95–97.5/99–99.5 | [87, 88, 90] |
| From whole blood                 |                                               |         | 73 Gram positives Staphylococcus spp., E. faecalis, E. faecium, S. lugdunensis, Streptococcus spp. | mecA, van A/B | 29–65/66–95 | [67, 68] |
(POCT) needs, however, are still scarce, and studies are still in progress to achieve FDA approval and CE mark [94].

Table 1 summarises performance of the main commercially available RDTs for bloodstream infections.

**Host Response and Transcriptomics**

Existing biomarkers provide a limited insight into the complex host response to infection, and consequently offer limited discrimination between infectious actiologies. Indeed, commonly used infection biomarkers offer only a binary outcome of severity of infection, or probability of bacterial infection to guide antibacterial use. There is growing interest in the role of omics technologies to interrogate the proteome, metabolome, epigenome or transcriptome to more comprehensively characterise infection phenotypes. Such biological classifiers are established in the fields of oncology [95] and cardiovascular disease [96], though the time-critical nature of infections in ICU adds a further challenge. Diagnostics based on differential gene expression in acute infections are of substantial interest. Classifiers such as the ‘Integrated Antibiotics Decision Model’ [97] and a ‘Disease Risk Score’ in febrile children [98] have undergone external validation to suggest they have potential value in guiding treatment decisions. Septicyte was the first such transcript-based infectious disease diagnostic to receive FDA approval in 2017 and continues to undergo external validation to demonstrate its value in different clinical contexts [99]. Transcript-based classifiers have the potential to characterise patients not only by pathogen (bacterial, viral or fungal) but by inflammatory phenotype thereby offering the possibility of successful personalised immunomodulation in sepsis [100]. Establishing the role of transcript-based disease classifiers in infections on ICU will require an understanding of how such assays can be performed in a timely way, and a demonstration of their impact, including cost-effectiveness, in clinical trials.

**How Should the Clinical Utility of Novel Rapid Diagnostics Be Evaluated?**

Reduced turn-around time (TAT) in either identification or susceptibility information is not sufficient to indicate the improved utility of a test, though it is an important component [101]. Other parameters include the sensitivity, specificity, type of result yielded and the confidence of the relevant clinician acting upon the result [102]. Arguably, a full assessment of the impact and value of rapid diagnostic microbiology technologies evaluates more than TATs and AMS outcomes. We need controlled trials or interrupted time series analyses over extended periods, evaluating multiple key clinical and process outcomes such as mortality, acute kidney injury, length of stay.

---

| Technology                              | Assay (manufacturer) | TAT (h) | Organisms detected                                      | Resistance genes detected | Sensitivity/ specificity (%) | Ref |
|-----------------------------------------|----------------------|---------|--------------------------------------------------------|---------------------------|-----------------------------|-----|
| PCR + miniaturised magnetic resonance   | T2Candida panel (T2  | 3–5     | 12 Gram negatives                                      |                           |                             |     |
|                                          | Biosystems)           |         | E. coli, K. pneumoniae, K. oxytoca, S. marcescens, B. fragilis, S. thypi, E. cloaca, E. aerogenes, P. mirabilis, P. aeruginosa, A. baumannii, S. maltophilia |                           |                             |     |
|                                          |                      |         | 6 fungi                                                 |                           |                             |     |
|                                          |                      |         | C. albicans, C. tropicalis, C. parapsilosis, C. krusei, C. glabrata, A. fumigatus |                           |                             |     |
| T2Bacteria panel (T2 Biosystems)        | 4–7                  |         | E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, E. coli |                           |                             |     |
| SepsiTest (Molzym)                      | 8–18                 |         | Over 345 bacteria and 8 fungi                          |                           |                             |     |
| Untargeted NGS                          | iDTECT Dx Blood      | 60a     | Over 1200 pathogens (bacteria and viruses)            |                           |                             |     |
| (PathoQuest)                            |                      |         |                                                        | (Negative predictive value: 98.4%) |                             |     |
| Untargeted NGS                          | Karius NGS plasma    | 53a     | Over 1200 pathogens (bacteria, fungi, viruses and parasites) |                           |                             |     |
|                                         | Test (Karius)         |         |                                                        | 93/63                     |                             |     |

*TAT, turn-around time; PCR, polymerase chain reaction; MRSA, methicillin-resistant S. aureus; CoNS, coagulase-negative staphylococci; PNA, peptide nucleic acid; FISH, fluorescent in situ hybridisation; AST, antimicrobial susceptibility testing; MIC, minimum inhibitory concentration; ID, identification

*Including sample shipment*
and readmission. This would ideally be combined with a comprehensive cost-effectiveness analysis, assessing not only hospital admission costs, but value of quality-adjusted-life-year (QALY) saved, costs of laboratory implementation of RDT programs and adjunct AMS programs.

There is a paucity of high-quality evidence in this field, though there are numerous quasi-studies that have evaluated AMS outcomes with several incorporating a selection of clinical or process outcomes [45, 103, 104]. The most consistent, though not universal finding, has been that rapid technologies alone do not translate even to better AMS outcomes, let alone improved clinical outcomes, without also embedding customised AMS support strategies and this is reflected in the Infectious Diseases Society of America (IDSA) guidelines [45, 52, 101, 105, 106].

Targeted AMS strategies that have been evaluated to support implementation of RDT range from extended hours of the service, notification of critical results to a member of the AMS team who provides targeted direct advice and other activities that increase clinical interaction [105, 107]. When these strategies are coupled with RDTs, improvements in optimal antimicrobial use and de-escalation are the most consistent findings, with cost saving the least represented [45, 108, 109]. Impact on clinical outcomes has been highly variable in studies assessing length of stay, mortality and re-admission [110–112]. The reasons for this have not been rigorously studied but based on other stewardship research likely pertain to prescribing behaviour, lack of familiarity, and experience or expert knowledge in the actionability of RDT results [113, 114]. The likelihood of a clinical de-escalation of antimicrobials overnight is low, even if microbiology and AMS teams extend their hours of operation for a 24/7 model, reflecting caretaker culture overnight [105].

The most actionable results include (i) identification of likely contaminants and (ii) detection of a molecular target correlated with resistance not covered by the empiric regimen. One of the molecular RDTs most rigorously assessed for AMS and clinical impact has been the Verigen system. The results for Gram-positive BC organisms were demonstrably more actionable than for Gram negatives, reflecting both the complexity of genetic markers of resistance and the morbidity and mortality associated with early suboptimal treatment of Gram-negative sepsis [105]. Multiplexed PCR assays are limited in the number of target genes that can be identified and do not comprehensively cover all relevant resistance mechanisms. Despite this, Verigen has outperformed clinical risk tools for predicting third-generation cephalosporin resistance, though the applicability of this result will be variable depending on the community prevalence of ESBL, in particular [107]. Another significant limitation of most molecular RDT systems is the suboptimal sensitivity in detecting polymicrobial infection limiting confidence in de-escalation [105].

Implementation of molecular RDTs is a relatively resource-intensive measure and current technologies are not standalone tests. Conventional phenotypic testing would still need to be performed, particularly for AST [115]. As discussed above, molecular RDT does have some significant limitations including decreased sensitivity in detecting polymicrobial bacteremia, the potential for cross-contamination or genetic similarity (e.g. Shigella and E. coli), the restricted range of resistance mechanisms and the lack of clinically validated correlation of genetic makers with minimum inhibitory concentrations (MICs). The latter can be critical to therapeutic drug monitoring and wild-type surveillance or to determine suitability of use of an agent such as meropenem even in the presence of a carbapenemase. Phenotypic RDTs and biomarkers are also usually utilised in conjunction with conventional testing. Improved cost-efficiencies can be associated with targeted use for critically unwell patients, specifically within intensive care, haematology and oncology [113].

Demonstrating benefits from introduction of such services will depend on the institution including local antibiograms, patient complexity and strength of current AMS, and interactions with microbiology and infectious disease teams [109]. Low- and middle-income nations with high rates of community multidrug-resistant organisms may find the costs of molecular methods prohibitive but rapid phenotypic tests or optical sensor portable low footprint techniques may have a significant role [116].

Point of Care Diagnostics

Most of the methods discussed thus far require a well-functioning laboratory, with at least a basic requirement for scientific skills and training. Only assays which are simple to use and have a low risk of incorrect results are generally approved for POCT, with higher complexity tests reserved for suitably equipped laboratories. However, using a laboratory-based test introduces some delay and a degree of distance from the patient and treating clinicians. In geographically dispersed countries with remote locations, this can result in major delays for critical tests such as BCs or molecular diagnostics. In Australia, as in most other jurisdictions, organisations offering POCT must adhere to certain standards that define appropriate governance, maintenance of test integrity, minimisation of pre-analytical, analytical and post-analytical errors, provision of suitable training and competency assessment, with all such processes embedded within a robust quality management system [117]. Such processes have evolved over time to ensure that clinicians have confidence in test results they receive. Currently, no POCT exists for the accurate diagnosis of bloodstream infections or most other critical infections. The future holds some hope for technological advances such as microfluidic devices that can integrate
sampling and signal generation within a POCT setting, maybe using testing platforms such as “on-chip” immunoassays or nucleic acid analysis. Such technology can, in theory, incorporate all the key steps of molecular detection: cell lysis and extraction, nucleic acid purification, amplification and detection of reaction products. Such miniaturisation may also allow multiplexing to enable high-throughput testing within a single portable device [118]. There is substantial pre-clinical research into the design, construction materials and detection technologies for such devices, but as yet no commercial products are ready for clinical evaluation.

Conclusions

It is likely that a number of new microbiological methods will enhance our capacity to rapidly and accurately identify pathogens in critically unwell patients. However, well-designed studies assessing key clinical outcomes are needed to define their role in improving the management of severe infections.

Availability of Data and Material Not applicable
Code Availability Not applicable

Declarations

Conflict of Interest PNAH reports grants from Shionogi, MSD and Sandoz, as well as personal fees from Sandoz and Pfizer, outside the submitted work. All the other authors declare no conflicts of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

1. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344–53.
2. Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med. 2012;40(3):756–61.
3. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.
4. Denny KJ, De Waele J, Laupland KB, Harris PNA, Lipman J. When not to start antibiotics: avoiding antibiotic oversuse in the intensive care unit. Clin Microbiol Infect. 2020;26(1):35–40.
5. Hall KK, Lyman JA. Updated review of blood culture contamination. Clin Microbiol Rev. 2006;19(4):788–802.
6. Murray PR, Masur H. Current approaches to the diagnosis of bacterial and fungal bloodstream infections in the intensive care unit. Crit Care Med. 2012;40(12):3277–82.
7. Rodriguez-Sanchez B, Cercenado E, Coste AT, Greub G. Review of the impact of MALDI-TOF MS in public health and hospital hygiene, 2018. Euro Surveill. 2019;24(4):1800193.
8. Messacar K, Parker SK, Todd JK, Dominguez SR. Implementation of rapid molecular infectious disease diagnostics: the role of diagnostic and antimicrobial stewardship. Journal of clinical microbiology. 2017;55(3):715–23.
9. Trotter AJ, Aydin A, Strinden MJ, O’Grady J. Recent and emerging technologies for the rapid diagnosis of infection and antimicrobial resistance. Curr Opin Microbiol. 2019;51:39–45.
10. Minassian AM, Newnham R, Kalimeris E, Bejon P, Atkins BL, Bowler IC. Use of an automated blood culture system (BD BACTEC) for diagnosis of prosthetic joint infections: easy and fast. BMC Infect Dis. 2014;14:233.
11. Li Z, Liu S, Chen H, Zhang X, Ling Y, Zhang N, et al. Comparative evaluation of BACTEC FX, BacT/ALERT 3D, and BacT/ALERT VIRTUO-automated blood culture systems using simulated blood cultures. Acta Clin Belg. 2020:1–8.
12. Menchinelli G, Liotti FM, Fiori B, De Angelis G, D’Inzeo T, Giordano L, et al. In vitro Evaluation of BACT/ALERT(R) VIRTUO(R), BACT/ALERT 3D(R), and BACTEC FX automated blood culture systems for detection of microbial pathogens using simulated human blood samples. Front Microbiol. 2019;10:221.
13. Chung Y, Kim IH, Han M, Kim HS, Kim HS, Song W, et al. A comparative evaluation of BACT/ALERT FA PLUS and FN PLUS blood culture bottles and BD BACTEC Plus Aerobic and Anaerobic blood culture bottles for antimicrobial neutralization. Eur J Clin Microbiol Infect Dis. 2019;38(12):2229–33.
14. Somily AM, Habib HA, Torchyana AA, Sayyed SB, Absar M, Al-Aqeel R, et al. Time-to-detection of bacteria and yeast with the BACTEC FX versus BacT/Alert VIRTuo blood culture systems. Ann Saudi Med. 2018;38(3):194–9.
15. Park J, Han S, Shin S. Comparison of growth performance of the BacT/ALERT VIRTUO and BACTEC FX Blood Culture Systems under simulated bloodstream infection conditions. Clin Lab. 2017;63(1):39–46.
16. Chen IH, Nicolau DP, Kuti JL. Effect of clinically meaningful antibiotic concentrations on recovery of Escherichia coli and Klebsiella pneumoniae isolates from anaerobic blood culture bottles with and without antibiotic binding resins. J Clin Microbiol. 2019;57(12).
17. Chen IH, Nicolau DP, Kuti JL. Recovery of Gram-negative bacteria from aerobic blood culture bottles containing antibiotic binding resins after exposure to beta-lactam and fluoroquinolone concentrations. J Clin Microbiol. 2019;57(10).
18. Wilson ML, Weinstein MP, Reller LB. Automated blood culture systems. Clin Lab Med. 1994;14(1):149–69.
19. Edmiston CE, Garcia R, Barnden M, DeBaun B, Johnson HB. Rapid diagnostics for bloodstream infections: a primer for infection preventionists. American journal of infection control. 2018;46(9):1060–8.
20. Smith KP, Kang AD, Kirby JE. Automated interpretation of blood culture Gram stains by use of a deep convolutional neural network. J Clin Microbiol. 2018;56(3).
21. Qian Q, Eichelberger K, Kirby JE. Rapid identification of Staphylococcus aureus in blood cultures by use of the direct tube coagulase test. J Clin Microbiol. 2007;45(7):2267–9.
22. Ozem NS, Ogrene D, Mutlu D, Ongul G, Baysan BO, Gunseren F. Comparison of four methods for rapid identification of Staphylococcus aureus directly from BACTEC 9240 blood culture system. Indian J Med Microbiol. 2011;29(1):42–6.
23. Chandrasekaran S, Abbott A, Campeau S, Zimmer BL, Weinstein M, Thrupp L, et al. Direct-from-blood-culture disk diffusion to determine antimicrobial susceptibility of Gram-negative bacteria: preliminary report from the Clinical and Laboratory Standards
24. Jonasson E, Matuschek E, Kahlmeter G. The EUCAST rapid disc diffusion method for antimicrobial susceptibility testing directly from positive blood culture bottles. J Antimicrob Chemother. 2020;75(4):968–78.

25. Kumar M, Shergill SPS, Tandel K, Sahai K, Gupta RM. Direct antimicrobial susceptibility testing from positive blood culture bottles in laboratories lacking automated antimicrobial susceptibility testing systems. Med J Armed Forces India. 2019;75(4):450–7.

26. Bayraktar B, Baris A, Malkocoglu G, Erdemir D, Kina N. Comparison of Carba NP-direct, carbapenem inactivation method, and beta-CARBA tests for detection of carbapenemase production in Enterobacteriaceae. Microb Drug Resist. 2019;25(1):97–102.

27. Cunningham SA, Limbago B, Traczekowski M, Anderson K, Hackel M, Hindler J, et al. Multicenter performance assessment of Carba NP Test. J Clin Microbiol. 2017;55(6):1954–60.

28. McMullen AR, Wallace MA, LaBombardi V, Hindler J, Canpeau S, Humphries R, et al. Multicenter evaluation of the RAPID(CR) CARBA NP assay for the detection of carbapenemase production in clinical isolates of Enterobacteriales and Pseudomonas aerugi nosa. Eur J Clin Microbiol Infect Dis. 2020;39(11):2037–44.

29. Blanc DS, Poncet F, Grandbastien B, Greub G, Senn L, Nordmann P. Evaluation of the performance of rapid tests for screening carriers of acquired ESBL producers and their impact on the turnaround time. J Hosp Infect. 2020.

30. Couturier MR, Graf EH, Griffin AT. Urine antigen tests for the diagnosis of respiratory infections: legionellosis, histoplasmosis, pneumococcal pneumonia. Clin Lab Med. 2014;34(2):219–36.

31. Viasus D, Calatayud L, McBrown MV, Ardanuy C, Carratala J. Urinary antigen testing in community-acquired pneumonia in adults: an update. Expert Rev Anti Infect Ther. 2019;17(2):107–15.

32. Avni T, Bieber A, Green H, Steinmetz T, Leibovici L, Paul M. Diagnostic accuracy of PCR alone and compared to urinary antigen testing for detection of Legionella spp.: a systematic review. J Clin Microbiol. 2016;54(2):401–11.

33. Baggett HC, Rhodes J, Deisirietlt S, Salika P, Wansom T, Jorakate P, et al. Pneumococcal antigen testing of blood culture broth to enhance the detection of Streptococcus pneumoniae bacteremia. Eur J Clin Microbiol Infect Dis. 2012;31(5):753–6.

34. Kassis C, Zaidi S, Kuberski T, Moran A, Gonzalez O, Hussain S, et al. Role of Coccidioides antigen testing in the cerebrospinal fluid for the diagnosis of coccidioidal meningitis. Clin Infect Dis. 2015;61(10):1521–6.

35. Porcel JM. Biomarkers in the diagnosis of pleural diseases: uses, limitations, and future applications in acute-care settings. Lancet Infect Dis. 2016;16(7):819–27.

36. Perkins MD, Mirrett S, Reller LB. Rapid bacterial antigen detection of Carba NP-direct, carbapenem inactivation method, and beta-CARBA tests for detection of carbapenemase production in Enterobacteriaceae. Microb Drug Resist. 2019;25(1):97–102.

37. Andrews D, Chetty Y, Cooper BS, Vark M, Glass SK, Letters A, et al. Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use. BMC Infect Dis. 2017;17(1):671.

38. Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. Lancet Infect Dis. 2004;4(6):337–48.

39. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15.

40. Cui N, Zhang H, Chen Z, Yu Z. Prognostic significance of PCT and CRP evaluation for adult ICU patients with sepsis and septic shock: retrospective analysis of 59 cases. J Int Med Res. 2019;47(4):1573–9.

41. van den Brul A, Thompson MJ, Haj-Hassan T, Stevens R, Moll H, Lakanpal M, et al. Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review. BMJ. 2011;342:d3082.

42. Grundman I, Pirvu A, Riza A, Ioana M, Netea MG. Biomarkers of inflammation and the etiology of sepsis. Biochem Soc Trans. 2020;48(1):1–14.

43. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819–27.

44. Stocker M, van Herk W, El Helou S, Dutta S, Fontana MS, Schuerman F, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPls). Lancet. 2017;390(10097):871–81.

45. Timbrook TT, Morton JB, McConkey KW, Caffrey AR, Meliakis E, LaPlante KL. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis. 2017;64(1):15–23.

46. Tansarl KS, Chopin KC. Diagnostic test accuracy of the BioFire FilmArray(R) meningitis/encephalitis panel: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26(3):281–90.

47. Dack K, Pankow S, Ablah E, Zuckula R, Assi M. Contribution of the BioFire(R) FilmArray(R) meningitis/encephalitis panel: assessing antimicrobial duration and length of stay. Kans J Med. 2019;12(1):1–3.

48. Moftia MA, Bremmer DN, Carr D, Buchanan C, Shively NR, Elufuyi R, et al. Impact of a multiplex polymerase chain reaction assay on the clinical management of adults undergoing a lumbar puncture for suspected community-onset central nervous system infections. Antibiotics (Basel). 2020;9(6).

49. Maataoui N, Chemali L, Patrier J, Tran Dinh A, Le Frevre L, Lortat-Jacob B, et al. Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit. Eur J Clin Microbiol Infect Dis. 2021.

50. Vandendriessche S, Padalko E, Wollants E, Verfaillie C, Verhasselt B, Coorevits L. Evaluation of the Seegene Allplex Respiratory Panel for diagnosis of acute respiratory tract infections. Acta Clin Belg. 2019;74(6):379–85.

51. Blaschke AJ, Heyrend C, Byington CL, Fisher MA, Shively NR, Elufuyi R, et al. Impact of a multiplex polymerase chain reaction assay on the clinical management of adults undergoing a lumbar puncture for suspected community-onset central nervous system infections. Antibiotics (Basel). 2020;9(6).

52. Southern TR, VanSchooneveld TC, Bannister DL, Brown TL, Crisman AS, Buss SN, et al. Implementation and performance of the BioFire FilmArray(R) BCID panel kit for bronchoalveolar lavage analysis. Mol Biol Rep. 2019;46(3):2685–92.

53. Dack K, Pankow S, Ablah E, Zuckula R, Assi M. Contribution of the BioFire(R) FilmArray(R) meningitis/encephalitis panel: assessing antimicrobial duration and length of stay. Kans J Med. 2019;12(1):1–3.

54. Moftia MA, Bremmer DN, Carr D, Buchanan C, Shively NR, Elufuyi R, et al. Impact of a multiplex polymerase chain reaction assay on the clinical management of adults undergoing a lumbar puncture for suspected community-onset central nervous system infections. Antibiotics (Basel). 2020;9(6).

55. Maataoui N, Chemali L, Patrier J, Tran Dinh A, Le Frevre L, Lortat-Jacob B, et al. Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit. Eur J Clin Microbiol Infect Dis. 2021.

56. Vandendriessche S, Padalko E, Wollants E, Verfaillie C, Verhasselt B, Coorevits L. Evaluation of the Seegene Allplex Respiratory Panel for diagnosis of acute respiratory tract infections. Acta Clin Belg. 2019;74(6):379–85.

57. Blaschke AJ, Heyrend C, Byington CL, Fisher MA, Shively NR, Elufuyi R, et al. Impact of a multiplex polymerase chain reaction assay on the clinical management of adults undergoing a lumbar puncture for suspected community-onset central nervous system infections. Antibiotics (Basel). 2020;9(6).

58. Maataoui N, Chemali L, Patrier J, Tran Dinh A, Le Frevre L, Lortat-Jacob B, et al. Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit. Eur J Clin Microbiol Infect Dis. 2021.
57. Mancini N, Infurnari L, Ghidoli N, Valzano G, Clementi N, Burioni R, et al. Potential impact of a microarray-based nucleic acid assay for rapid detection of Gram-negative bacteria and resistance markers in positive blood cultures. J Clin Microbiol. 2014;52(4):1242–5.

58. Buchan BW, Ginocchio CC, Manii R, Cavagnolo R, Pancholi P, Sweeney L, et al. Multiplex identification of gram-positive bacteria and resistance determinants directly from positive blood culture broth: evaluation of an automated microarray-based nucleic acid test. PLoS Med. 2013;10(7):e1001478.

59. Evans SR, Tran TTT, Hujer AM, Hill CB, Hujer KM, Mediavilla JR, et al. Rapid molecular diagnostics to inform empiric use of ceftazidime/avibactam and cefepime/tazobactam against Pseudomonas aeruginosa: PRIMERS IV. Clin Infect Dis. 2019;68(11):1823–30.

60. Claeyts KC, Heil EL, Hitchcock S, Johnson JK, Leekha K. Management of Gram-negative bloodstream infections in the era of rapid diagnostic testing: impact with and without antibiotic stewardship. Open Forum Infect Dis. 2020;7(10):ofaa427.

61. Tribble AC, Gerber JS, Bilker WB, Lautenbach E. Impact of rapid diagnostics with antimicrobial stewardship support for children with positive blood cultures: a quasi-experimental study with time trend analysis. Infect Control Hosp Epidemiol. 2020;41(8):883–90.

62. Laub RR, Knudsen JD. Clinical consequences of using PNA-FISH in Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 2014;33(4):599–601.

63. Cosgrove SE, Li DX, Tamma PD, Avdic E, Hadhazy E, Wakefield T, et al. Use of PNA FISH for blood cultures growing Gram-positive cocci in chains without a concomitant antibiotic stewardship intervention does not improve time to appropriate antibiotic therapy. Diagn Microbiol Infect Dis. 2016;86(1):86–92.

64. Stevenson M, Pandor A, Martyn-St James M, Rafia R, Utley L, Stevens J, et al. Septis: the LightCycler SeptiFast Test MGRADE(R), SeptiTest and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation. Health Technol Assess. 2016;20(46):1–246.

65. Dark P, Blackwood B, Gates S, McAuley D, Perkins GD, McMullan R, et al. Accuracy of LightCycler(r)(R) SeptiFast for the detection and identification of pathogens in the blood of patients with suspected sepsis: a systematic review and meta-analysis. Intensive Care Med. 2015;41(1):21–33.

66. Chang SS, Hsieh WH, Liu TS, Lee SH, Wang CH, Chou HC, et al. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysis. PLoS One. 2013;8(5):e62233.

67. Ziegler I, Fagerstrom A, Stralin K, Molling P. Evaluation of a commercial multiplex PCR assay for detection of pathogen DNA in blood from patients with suspected sepsis. PLoS One. 2016;11(12):e0167883.

68. Zborowsyrska Y, Cilloniz C, Cabos-Trigueros N, Almela M, Hurtado JC, Vergara A, et al. Evaluation of the MagiLEX Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults. Front Cell Infect Microbiol. 2019;9:56.

69. Pfäffler MA, Wolk DM, Lowery TJ. T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. Future Microbiol. 2016;11(1):103–17.

70. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Varquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60(6):892–9.

71. Clancy CJ, Nguyen MH. T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward. J Antimicrob Chemother. 2018;73(suppl 4)i1:i2–5.

72. De Angelis G, Posterraro B, De Carolis E, Menchinelli G, Franceschi F, Tumarello M, et al. T2Bacteria magnetic resonance assay for the rapid detection of ESKAPEc pathogens directly in whole blood. J Antimicrob Chemother. 2018;73(suppl 4):i20–i6.

73. Nguyen MH, Clancy CJ, Pasculle AW, Pappas PG, Alangaden G, Pankey GA, et al. Performance of the T2Bacteria panel for diagnosing bloodstream infections: a diagnostic accuracy study. Ann Intern Med. 2019;170(12):845–52.

74. Maki DG. The T2Bacteria Panel had 90% sensitivity for detecting targeted organisms, 43% for any bloodstream infection organism. Ann Intern Med. 2019;171(6):JC34.

75. Weinreb DB, Capraro GA. The uncertain clinical benefit of the T2Bacteria panel. Ann Intern Med. 2019;170(12):888–9.

76. Oros D, Ceprnga M, Zucko J, Cindric M, Hozic A, Skrin J, et al. Identification of pathogens from native urine samples by MALDI-TOF/TOF tandem mass spectrometry. Clin Proteomics. 2020;17:25.

77. Brunetti G, Ceccarelli G, Giordano A, Navazio AS, Vittozzi P, Venditti M, et al. Fast and reliable diagnosis of XDR Acinetobacter baumannii meningitis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. New Microbiol. 2018;41(1):77–9.

78. Ozeneci V, Patel R, Ullberg M, Stralin K. Demise of polymerase chain reaction/electrospray ionization-mass spectrometry as an infectious diseases diagnostic tool. Clin Infect Dis. 2018;66(3):452–5.

79. Rutanga JP, Van Puyvelde S, Heroes AS, Muvunyi CM, Jacobs J, Deborggrave S. 16S metagenomics for diagnosis of bloodstream infections: opportunities and pitfalls. Expert Rev Mol Diagn. 2018;18(8):749–59.

80. Chiu CY, Miller SA. Clinical metagenomics. Nat Rev Genet. 2019;20(6):341–55.

81. Parize P, Muth E, Richaud C, Gratigny M, Pilms B, Lamamy A, et al. Untargeted next-generation sequencing-based first-line diagnosis of infection in immunocompromised adults: a multicentre, blinded, prospective study. Clin Microbiol Infect. 2017;23(8):574 e1–6.

82. Blauwkamp TA, Thair S, Rosen MJ, Blair L, Lindner MS, Vilfan ID, et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol. 2019;4(4):663–74.

83. Goggin KP, Gonzalez-Pena V, Inaba Y, Allison KJ, Hong DK, Ahmed AA, et al. Evaluation of plasma microbial cell-free DNA sequencing to predict bloodstream infection in pediatric patients with relapsed or refractory cancer. JAMA Oncol. 2020;6(4):552–6.

84. Niles DT, Wijetunge DSS, Palazzi DL, Singh IR, Revell PA. Plasma metagenomic next-generation sequencing assay for identifying pathogens: a retrospective review of test utilization in a large children’s hospital. J Clin Microbiol. 2020;58(11).

85. Hogan CA, Yang S, Garner OB, Green DA, Gomez CA, Dien BW, et al. Accuracy of LightCycler((R)) SeptiFast for identifying pathogens: a retrospective review of test utilization in a large children’s hospital. J Clin Microbiol. 2020;58(11).

86. Chiu CY, Miller SA. Clinical metagenomics. Nat Rev Genet. 2019;20(6):341–55.

87. Charnot-Katsikas A, Tesic V, Love N, Hill B, Bethel C, Boonlayangoor S, et al. Performance of the Magicplex system for rapid detection of pathogens from native urine samples by MALDI-TOF/TOF tandem mass spectrometry. Clin Proteomics. 2020;17:25.

88. Rutanga JP, Van Puyvelde S, Heroes AS, Muvunyi CM, Jacobs J, Deborggrave S. 16S metagenomics for diagnosis of bloodstream infections: opportunities and pitfalls. Expert Rev Mol Diagn. 2018;18(8):749–59.

89. Blauwkamp TA, Thair S, Rosen MJ, Blair L, Lindner MS, Vilfan ID, et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol. 2019;4(4):663–74.

90. Goggin KP, Gonzalez-Pena V, Inaba Y, Allison KJ, Hong DK, Ahmed AA, et al. Evaluation of plasma microbial cell-free DNA sequencing to predict bloodstream infection in pediatric patients with relapsed or refractory cancer. JAMA Oncol. 2020;6(4):552–6.

91. Niles DT, Wijetunge DSS, Palazzi DL, Singh IR, Revell PA. Plasma metagenomic next-generation sequencing assay for identifying pathogens: a retrospective review of test utilization in a large children’s hospital. J Clin Microbiol. 2020;58(11).

92. Hogan CA, Yang S, Garner OB, Green DA, Gomez CA, Dien BW, et al. Accuracy of LightCycler((R)) SeptiFast for identifying pathogens: a retrospective review of test utilization in a large children’s hospital. J Clin Microbiol. 2020;58(11).
89. Marschal M, Bachmaier J, Autenrieth I, Oberhettinger P, Willmann M, Peter S. Evaluation of the Accelerate Pheno System for fast identification and antimicrobial susceptibility testing from positive blood cultures in bloodstream infections caused by Gram-negative pathogens. J Clin Microbiol. 2017;55(7):2116–26.

90. Pancholi P, Carroll KC, Buchan BW, Chan RC, Dhiman N, Ford B, et al. Multicenter evaluation of the Accelerate PhenoTest BC kit for rapid identification and phenotypic antimicrobial susceptibility testing using morphokinetic cellular analysis. J Clin Microbiol. 2018;56(4).

91. Dubourg G, Raoult D. Emerging methodologies for pathogen identification in positive blood culture testing. Expert Rev Mol Diagn. 2016;16(1):97–111.

92. Lee M, Scardina T, Zheng X, Patel SJ. Clinical performance and impact of Accelerate Pheno for Gram-negative bacteremia in hospitalized patients. Clin Ther. 2020;42(9):1630–6.

93. Dare RK, Lusardi K, Pearson C, McCaig KD, Daniels B, Van S, et al. Clinical impact of Accelerate PhenoTM rapid blood culture detection system in bacteremic patients. Clin Infect Dis. 2020.

94. Vasala A, Hytonen VP, Laitinen OH. Modern tools for rapid diagnostics of antimicrobial resistance. Front Cell Infect Microbiol. 2020;10:308.

95. Hsueh EC, DeBloom JR, Lee J, Sussman J, Covington KR, Middlebrook B, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol. 2017;10(1):152.

96. Vargas J, Lima JA, Kraus WE, Douglas PS, Rosenberg S. Use of the Corus(R) CAD Gene expression test for assessment of obstructive coronary artery disease likelihood in symptomatic non-diabetic patients. PLoS Curr. 2013;5:ecurrents.e004f6081905999fa92b99593478aeab.

97. Sweeney TE, Wong HR, Khatri P. Robust classification of bacterial and viral infections via integrated host gene expression diagnostics. Sci Transl Med. 2016;8(346):346ra91.

98. Herberg JA, Kafourou M, Wright VJ, Shailes H, Eleftherohorinou H, Hoggart CJ, et al. Diagnostic test accuracy of a 2-transcript host RNA signature for discriminating bacterial vs viral infection in febrile children. JAMA. 2016;316(8):835–45.

99. Sampson D, Yager TD, Fox B, Shawleross L, McHugh L, Seldon T, et al. Blood transcriptomic discrimination of bacterial and viral infections in the emergency department: a multi-cohort observational validation study. BMC Med. 2020;18(1):185.

100. Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Endotype transitions during the acute phase of pediatric septic shock reflect changing risk and treatment response. Crit Care Med. 2018;46(3):e242–e9.

101. Palavecino EL, Williamson JC, Ohl CA. Collaborative antimicrobial stewardship: working with microbiology. Infect Dis Clin North Am. 2020;34(1):51–65.

102. Aamot HV, Noone JC, Skramm I, Leegaard TM. Are conventional microbiological diagnostics sufficiently efficient in the era of rapid diagnostics? Evaluation of conventional microbiological diagnostics of orthopedic implant-associated infections (OIAI). Acta Orthop. 2020;1–6.

103. Perez KK, Olsen RJ, Musick WL, Cernocho PL, Davis JR, Land GA, et al. Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Arch Pathol Lab Med. 2013;137(9):1247–54.

104. Huang AM, Newton D, Kamupuli A, Gandhi TN, Washer LL, Isip J, et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis. 2013;57(9):1237–45.

105. Juttukonda LJ, Katz S, Gillon J, Schmitz J, Banerjee R. Impact of a rapid blood culture diagnostic test in a children’s hospital depends on Gram-positive versus Gram-negative organism and day versus night shift. J Clin Microbiol. 2020;58(4).

106. Banerjee R, Teng CB, Cunningham SA, Ihde SM, Steckelberg JM, Moriarty JP, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis. 2015;61(7):1071–80.

107. Kwengros LN, Mynatt RP, Timbrook TT, Mitchell R, Salimnia H, Lephart P, et al. Minimizing time to optimal antimicrobial therapy for Enterobacteriaceae bloodstream infections: a retrospective, hypothetical application of predictive scoring tools vs rapid diagnostics tests. Open Forum Infect Dis. 2020;7(8):ofaa278.

108. Kondo M, Simon MS, Westblade LF, Jenkins SG, Babady NE, Loo AS, et al. Implementation of infectious diseases rapid molecular diagnostics and antimicrobial stewardship program involvement in acute-care hospitals. Infect Control Hosp Epidemiol. 2020;1–3.

109. She RC, Bender JM. Advances in rapid molecular blood culture diagnostics: healthcare impact, laboratory implications, and multiplex technologies. J Appl Lab Med. 2019;3(4):617–30.

110. Naseef F, El Lababidi R, Alatooom A, Krishnaprasad S, Bonilla F. The impact of integrating rapid PCR-based blood culture identification panel to an established antimicrobial stewardship program in the United Arab Emirates. Int J Infect Dis. 2020;91:124–8.

111. Mahrous AJ, Thabiti AK, Elarabi S, Fleisher J. Clinical impact of pharmacist-directed antimicrobial stewardship guidance following blood culture rapid diagnostic testing. J Hosp Infect. 2020;106(3):436–46.

112. Hogan CA, Eunju B, Watz N, Kapphahn K, Rigdon J, Mui E, et al. Impact of rapid antimicrobial susceptibility testing in Gram-negative rod bacteremia: a quasi-experimental study. J Clin Microbiol. 2020;58(9).

113. Faugno AK, Laidman AY, Perez Martinez JD, Campbell AJ, Blyth CC. Do rapid diagnostic methods improve antibiotic prescribing in paediatric bacteremia? J Paediatr Child Health. 2020.

114. Tseng AS, Kasule SN, Rice F, Mi L, Chan L, Seville MT, et al. Is It Actionable? An evaluation of the rapid PCR-based blood culture identification panel on the management of Gram-positive and Gram-negative blood stream infections. Open Forum Infect Dis. 2018;5(12):ofy308.

115. Oberhettinger P, Ziegler J, Autenrieth I, Marschal M, Peter S. Evaluation of two rapid molecular test systems to establish an algorithm for fast identification of bacterial pathogens from positive blood cultures. Eur J Clin Microbiol Infect Dis. 2020;39(6):1147–57.

116. Kapur S, Gehani M, Kammil K, Bharadwaj P, Nag V, Devara SM, et al. Clinical validation of innovative optical-sensor-based, low-cost, rapid diagnostic test to reduce antimicrobial resistance. J Clin Med. 2019;8(12).

117. National Pathology Accreditation Advisory Council (NPAAC). Guidelines for point of care testing. In: Department of Health, editor. 1st Edition ed 2015.

118. Kozel TR, Burnham-Manusch AR. Point-of-care testing for infectious diseases: past, present, and future. J Clin Microbiol. 2017;55(8):2313–20.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.